prikaz prve stranice dokumenta A case report of severe recurrent varicella in an ankylosing spondylitis patient treated with adalimumab – a new side effect after 15 years of usage
  Download
PDF 2.37 MB
Scientific paper - Case study
A case report of severe recurrent varicella in an ankylosing spondylitis patient treated with adalimumab – a new side effect after 15 years of usage
BMC Infectious Diseases, 19 (2019), 1; https://doi.org/10.1186/s12879-019-3768-y
Skuhala, Tomislava; Atelj, Anita; Prepolec, Jelena; Al-Mufleh, Mahmoud; Stanimirović, Andrija; Vukelić, Dalibor

Cite this document

Skuhala, T., Atelj, A., Prepolec, J., Al Mufleh, M., Stanimirović, A. & Vukelić, D. (2019). A case report of severe recurrent varicella in an ankylosing spondylitis patient treated with adalimumab – a new side effect after 15 years of usage. BMC Infectious Diseases, 19. (1). doi: 10.1186/s12879-019-3768-y

Skuhala, Tomislava, et al. "A case report of severe recurrent varicella in an ankylosing spondylitis patient treated with adalimumab – a new side effect after 15 years of usage." BMC Infectious Diseases, vol. 19, no. 1, 2019. https://doi.org/10.1186/s12879-019-3768-y

Skuhala, Tomislava, Anita Atelj, Jelena Prepolec, Mahmoud Al Mufleh, Andrija Stanimirović and Dalibor Vukelić. "A case report of severe recurrent varicella in an ankylosing spondylitis patient treated with adalimumab – a new side effect after 15 years of usage." BMC Infectious Diseases 19, no. 1 (2019). https://doi.org/10.1186/s12879-019-3768-y

Skuhala, T., et al. (2019) 'A case report of severe recurrent varicella in an ankylosing spondylitis patient treated with adalimumab – a new side effect after 15 years of usage', BMC Infectious Diseases, 19(1). doi: 10.1186/s12879-019-3768-y

Skuhala T, Atelj A, Prepolec J, Al Mufleh M, Stanimirović A, Vukelić D. A case report of severe recurrent varicella in an ankylosing spondylitis patient treated with adalimumab – a new side effect after 15 years of usage. BMC Infectious Diseases [Internet]. 2019 February 07 [cited 2024 April 21];19(1). doi: 10.1186/s12879-019-3768-y

T. Skuhala, A. Atelj, J. Prepolec, M. Al Mufleh, A. Stanimirović and D. Vukelić, "A case report of severe recurrent varicella in an ankylosing spondylitis patient treated with adalimumab – a new side effect after 15 years of usage", BMC Infectious Diseases, vol. 19, no. 1, February 2019. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:211515. [Accessed: 21 April 2024]

Please login to the repository to save this object to your list.
Metadata
Title (english)A case report of severe recurrent varicella in an ankylosing spondylitis patient treated with adalimumab – a new side effect after 15 years of usage
AuthorTomislava Skuhala
AuthorAnita Atelj
AuthorJelena Prepolec
AuthorMahmoud Al-Mufleh
AuthorAndrija Stanimirović
AuthorDalibor Vukelić
Author's institutionUniversity of Zagreb
School of Medicine
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Abstract (english)
BACKGROUND: Tumor necrosis factor-α (TNF-α) antagonists, most of which are monoclonal antibodies, became a widespread treatment for autoimmune diseases such as rheumatoid arthritis, ankylosing spondylitis, inflammatory bowel diseases, psoriasis, psoriatic arthritis, hidradenitis suppurativa and uveitis. Their use is based on the blockage of TNF-α, which plays an important role in granulomas formation, development of phagosomes, activation and differentiation of macrophages, immune response against viral pathogens. The multiple adverse effects of TNF-α inhibition have been identified, including a two-to four-fold increased risk of active tuberculosis and other granulomatous conditions and an increased occurrence of some other serious bacterial, fungal and certain viral infections. ----- CASE PRESENTATION: A 34-year-old male patient with disseminated varicella and pneumonitis was admitted to our hospital. The diagnosis of varicella was established serologically by enzyme immunoassay (EIA) and by polymerase chain reaction confirmation of the virus in vesicular fluid. The patient has been receiving adalimumab and methotrexate for the last 3 years due to ankylosing spondylitis and was seropositive to varicella zoster virus prior to the introduction of TNF-α antagonists. Acyclovir was administered for 10 days with the resolution of clinical illness and radiological signs of pneumonitis. CONCLUSION: Due to the use of biological agents, particularly TNF-α inhibitors, as a well-established therapy for some autoimmune diseases, new potential adverse events can be expected in the future and we wanted to point out one of them. To our knowledge this is the first case of recurrent disseminated varicella in a patient taking TNF-α antagonists.
Keywords (english)
Languageenglish
Publication typeScientific paper - Case study
Publication statusPublished
Peer reviewPeer review
Publication versionPublished version
Journal titleBMC Infectious Diseases
Numberingvol. 19, no. 1
p-ISSN1471-2334
DOIhttps://doi.org/10.1186/s12879-019-3768-y
URN:NBNurn:nbn:hr:105:211515
Publication2019-02-07
Document URLhttp://doi.org/10.1186/s12879-019-3768-y
Type of resourceText
Access conditionsOpen access
Terms of useLicence In copyright icon
Created on2024-03-28 10:28:44